Actively Recruiting
Artificial Intelligence in Mammography Screening in Norway
Led by Norwegian Institute of Public Health · Updated on 2026-01-14
150000
Participants Needed
1
Research Sites
444 weeks
Total Duration
On this page
Sponsors
N
Norwegian Institute of Public Health
Lead Sponsor
H
Helse Vest
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this randomized controlled trial is to compare the number of breast cancers detected among women who had their screening mammograms interpreted by artificial intelligence (AI) in combination with one or two breast radiologists to the number of breast cancers detected after standard independent double reading in BreastScreen Norway. The aims of the study is to prove that screening interpretation with AI in combination with one or two radiologists (the intervention) is non-inferior to standard interpretation procedure.
CONDITIONS
Official Title
Artificial Intelligence in Mammography Screening in Norway
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women attending the population-based mammography screening program BreastScreen Norway providing a signed, informed consent
You will not qualify if you...
- Women attending the population-based mammography screening program BreastScreen Norway not providing a signed, informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Registry of Norway, Norwegian Institute of Public Health
Oslo, Norway
Actively Recruiting
Research Team
S
Solveig Hofvind, PhD
CONTACT
Å
Åsne S Holen, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here